Navigation Links
Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
Date:7/28/2009

SAN FRANCISCO, July 28 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it will hold a conference call on Tuesday, August 4, 2009 to discuss the Company's second quarter 2009 results and provide a corporate update. Jerry McMahon, Ph.D., chairman and chief executive officer, Ronald A. Martell, president and chief operating officer, Greg Weaver, senior vice president and chief financial officer and Robert De Jager, M.D., chief medical officer, will host the call beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). A press release for the second quarter ended June 30, 2009, will be released after markets close on August 4.

To participate in the live call by telephone, please dial 888-515-2880 (United States) or 719-457-2652 (International). In addition, the live conference call is being Webcast and can be accessed on the "Events" page of the "News & Events" section of the Company's Web site at http://www.poniard.com. A replay of the Webcast will be available on the Company's Web site for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
2. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
3. Poniard Pharmaceuticals Files Shelf Registration
4. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
5. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
6. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
7. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
8. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
9. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
10. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
11. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... NetDimensions announced today that ... enhance training plan management for consistent implementation of standards and regulatory requirements across ... Group to help improve and streamline their training and employee development programs, which ...
(Date:3/28/2017)... ... 2017 , ... Triumph Modular Incorporated, and manufacturing partner NRB ... modular trade organization, were awarded First Place, as well as the prestigious Best ... Harvard University. The awards were presented at the 34th Annual World of Modular ...
(Date:3/28/2017)... 2017  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a ... therapies for metabolic and endocrine disorders, today announced that ... will deliver a corporate presentation at H.C. Wainwright & ... held April 3, 2017 at the St. Regis Hotel ... presentation are as follows: H.C. ...
(Date:3/28/2017)... 28, 2017 Focus is ... sector due to the scientifically intensive operations of ... agricultural, environmental, and industrial. In today,s pre-market research, Stock-Callers.com ... Inc. (NASDAQ: PTLA), OvaScience Inc. (NASDAQ: OVAS), Ocera ... (NASDAQ: OCUL ). Learn more about ...
Breaking Biology Technology:
(Date:3/1/2017)... , March 1, 2017  Aware, Inc. (NASDAQ: ... announced that Richard P. Moberg has resigned, ... co-President and Chief Financial Officer and Treasurer of Aware ... to serve as a member of the Board of ... , Aware,s co-Chief Executive Officer and co-President, General Counsel ...
(Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant kiosk ... At PTE 2017 ... Materna will present its complete end-to-end passenger journey, from ... benefit for passengers. To accelerate the whole passenger handling process, ... to take passengers through the complete integrated process with a ...
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber Ventures ... it has led a $3.5 million investment in  Polarity ... Strategic Cyber Ventures is DC based and is led ... Hank Thomas . Ron Gula , also a ... also participated in this series A round of funding. ...
Breaking Biology News(10 mins):